Carlsmed Revenue Rises 65% in Third Quarter

The Carlsbad, California spinal implant maker raised its full-year 2026 revenue outlook to $78 million to $80 million.

Updated on Nov. 10, 2026 in Healthcare

Carlsmed Revenue Rises 65% in Third Quarter

Carlsmed, Inc. reported third quarter 2026 revenue of $21.6 million, up 65% from $13.1 million a year earlier. The company also raised its full-year 2026 revenue guidance to a range of $78 million to $80 million.

Why it matters

The growth reflects increased inpatient reimbursement for aprevo lumbar procedures under the CMS fiscal year 2027 inpatient payment rule, which took effect October 1, 2026. Operating expenses rose to $29.4 million, leaving the company with a net loss of $12.2 million for the quarter.

Q3 2026 gross profit reached $16.7 million, while operating expenses rose to $29.4 million from $19.0 million, including $2.8 million tied to executive transition costs and expected resolution of certain legal matters. Cash, investments and restricted cash totaled $80.3 million as of September 30, 2026.

The players

Carlsmed, Inc.

A Carlsbad, California medical device company focused on personalized spinal implant technology for lumbar fusion surgery.

The details

Carlsmed's aprevo Lumbar Bi-lateral Posterior System launched in October 2026. The company said it grew its surgeon user base by more than 60% over the prior year and estimates the system addresses about 30,000 U.S. lumbar fusion procedures annually. Jeff Bertolini was promoted to Chief Operating Officer, Rich Heppenstall was named Chief Financial Officer, and Tony Jarc, Ph.D., was added as Chief Product and AI Officer.

Timeline

  1. October 1, 2026: CMS fiscal year 2027 inpatient payment rule with increased aprevo reimbursement took effect.

  2. October 2026: Carlsmed launched the aprevo Lumbar Bi-lateral Posterior System.

  3. September 30, 2026: Quarter ended with $80.3 million in cash and securities.

  4. November 10, 2026: Third quarter results were reported and full-year guidance raised.

Industry Dynamics

Carlsmed's revenue growth is tied directly to the CMS fiscal year 2027 inpatient payment rule, which raised reimbursement for lumbar procedures using its aprevo system. The company's results show how Medicare payment policy can shift revenue for specialized spinal implant makers.

Patients undergoing lumbar fusion surgery may see aprevo-based procedures more widely available as hospitals adopt the system under higher inpatient reimbursement. Hospital pricing and insurance coverage decisions will determine how the cost changes reach patients.

The takeaway

Revenue growth at medical device companies can depend heavily on federal reimbursement decisions, so changes to CMS payment rules are worth watching. Companies with rising sales may still post losses while they expand operations.

Further reading

For broader context on hospital and device reimbursement trends, explore more Healthcare coverage.

Source note: This article includes information reported by The Manila times.